$14.97
0.755.27%
In chiusura: -
$14.35
-0.62-4.14%
After hour: 9:29 AM EDT
Avalo Therapeutics segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di Avalo Therapeutics utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
AVTX | Avalo Therapeutics | -$2.83 | -$1.65 | — | — | $249.00K | — | — | — | 11/06/2025 | |
AVTX | Avalo Therapeutics | -$14.07 | -$1.46 | -$1.92 | -31.51% | $0.00 | — | $0.00 | — | 08/07/2025 | |
AVTX | Avalo Therapeutics | -$141.14 | -$1.61 | -$1.25 | 22.36% | $0.00 | — | $0.00 | — | 05/12/2025 | |
AVTX | Avalo Therapeutics | -$10.12 | -$1.39 | $1.72 | 223.74% | $571.00K | — | $192.00K | — | 03/20/2025 | |
AVTX | Avalo Therapeutics | -$26.40 | -$1.45 | -$2.83 | -95.17% | $236.00K | — | $249.00K | — | 11/07/2024 | |
AVTX | Avalo Therapeutics | -$141.60 | -$6.70 | -$14.07 | -110.00% | $643.00K | — | $0.00 | — | 08/12/2024 | |
AVTX | Avalo Therapeutics | -$204.00 | -$1.18 | -$6.11 | -417.80% | $475.00K | — | $0.00 | — | 05/13/2024 | |
AVTX | Avalo Therapeutics | -$249.60 | -$4.80 | -$10.12 | -110.83% | $896.00K | $300.00K | $571.00K | 90.33% | 03/29/2024 | |
AVTX | Avalo Therapeutics | $81.60 | -$264.00 | -$26.40 | 90.00% | $14.95M | $1.00M | $236.00K | -76.40% | 11/09/2023 | |
AVTX | Avalo Therapeutics | -$331.20 | -$192.00 | -$141.60 | 26.25% | $1.03M | $500.00K | $643.00K | 28.60% | 08/03/2023 | |
AVTX | Avalo Therapeutics | -$576.00 | -$232.80 | -$204.00 | 12.37% | $1.17M | $1.00M | $475.00K | -52.50% | 05/04/2023 | |
AVTX | Avalo Therapeutics | -$460.80 | -$175.20 | -$249.60 | -42.47% | $219.00K | $3.61M | $896.00K | -75.18% | 03/29/2023 | |
AVTX | Avalo Therapeutics | -$499.20 | -$261.60 | $81.60 | 131.19% | $1.35M | $1.08M | $14.95M | 1284.17% | 11/07/2022 | |
AVTX | Avalo Therapeutics | -$2.16 | -$424.80 | -$331.20 | 22.03% | $3.35M | $790.00K | $1.03M | 30.76% | 08/04/2022 | |
AVTX | Avalo Therapeutics | -$3.84 | -$374.40 | -$576.00 | -53.85% | $473.00K | $370.00K | $1.17M | 217.03% | 05/05/2022 | |
AVTX | Avalo Therapeutics | -$2.28 | — | -$460.80 | — | $1.50M | — | $219.00K | — | 03/02/2022 | |
AVTX | Avalo Therapeutics | -$1.92 | -$518.40 | -$489.60 | 5.56% | $1.11M | $1.12M | $1.35M | 20.54% | 11/09/2021 | |
AVTX | Avalo Therapeutics | -$2.16 | -$1.92 | -$2.16 | -12.50% | $1.34M | $4.20M | $3.35M | -20.12% | 08/02/2021 | |
AVTX | Avalo Therapeutics | -$4.32 | -$1.92 | -$3.84 | -100.00% | $2.75M | $4.20M | $473.00K | -88.74% | 05/13/2021 | |
AVTX | Avalo Therapeutics | -$1.20 | — | -$2.28 | — | $3.44M | — | $1.50M | — | 03/08/2021 | |
AVTX | Avalo Therapeutics | -$0.84 | — | -$1.92 | — | $5.61M | — | $1.11M | — | 11/09/2020 |
Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
---|---|---|---|---|
Q2 | 2025-08-07 | $-1.92 | $-1.46 | -31.5 % |
Q1 | 2025-05-12 | $-1.25 | $-1.61 | 22.4 % |
Q4 | 2025-03-20 | $1.72 | $-1.39 | 223.7 % |
Q3 | 2024-11-07 | $-2.83 | $-1.45 | -95.2 % |
Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
---|---|---|---|---|
Q4 | 2024-03-29 | $571.00K | $300.00K | 90.3 % |
Q3 | 2023-11-09 | $236.00K | $1.00M | -76.4 % |
Q2 | 2023-08-03 | $643.00K | $500.00K | 28.6 % |
Q1 | 2023-05-04 | $475.00K | $1.00M | -52.5 % |
Si prevede che Avalo Therapeutics (AVTX) fornisca risultati il novembre 6, 2025. Gli ultimi risultati sono stati pubblicati il agosto 7, 2025 per il Q2.
L'EPS effettivo era $-1.92, che mancato la stima di $-1.46.
Le entrate effettive sono state $0K, che centrato la stima di $0K.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.